| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
NanoGroup S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł1.03 |
| 52 Week High | zł1.30 |
| 52 Week Low | zł0.85 |
| Beta | 0.83 |
| 1 Month Change | -0.49% |
| 3 Month Change | 7.44% |
| 1 Year Change | -13.50% |
| 3 Year Change | -82.33% |
| 5 Year Change | -65.83% |
| Change since IPO | -77.22% |
Recent News & Updates
Shareholder Returns
| NNG | PL Life Sciences | PL Market | |
|---|---|---|---|
| 7D | -0.5% | -3.5% | 1.4% |
| 1Y | -13.5% | -9.2% | 26.6% |
Return vs Industry: NNG underperformed the Polish Life Sciences industry which returned -9.2% over the past year.
Return vs Market: NNG underperformed the Polish Market which returned 26.6% over the past year.
Price Volatility
| NNG volatility | |
|---|---|
| NNG Average Weekly Movement | 3.6% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in PL Market | 9.8% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: NNG has not had significant price volatility in the past 3 months.
Volatility Over Time: NNG's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Przemyslaw Mazurek | nanogroup.eu |
NanoGroup S.A. operates as a biotechnology company in Poland. The company develops and licenses early-stage pre-clinical and IND solutions to international biotech and pharma companies. It also manages a portfolio of companies that manages projects for the need of modern medicine in the field of oncology and transplantology.
NanoGroup S.A. Fundamentals Summary
| NNG fundamental statistics | |
|---|---|
| Market cap | zł20.60m |
| Earnings (TTM) | -zł1.82m |
| Revenue (TTM) | n/a |
-878.4x
P/S Ratio-11.3x
P/E RatioIs NNG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NNG income statement (TTM) | |
|---|---|
| Revenue | -zł23.45k |
| Cost of Revenue | zł391.78k |
| Gross Profit | -zł415.23k |
| Other Expenses | zł1.40m |
| Earnings | -zł1.82m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
May 29, 2024
| Earnings per share (EPS) | -0.09 |
| Gross Margin | 1,770.65% |
| Net Profit Margin | 7,746.33% |
| Debt/Equity Ratio | 0% |
How did NNG perform over the long term?
See historical performance and comparison